Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer

被引：4
作者：
Kogawa, Takahiro
Yonemori, Kan
Naito, Yoichi
Noguchi, Emi
Shimizu, Chikako
Tamura, Kenji
Hosono, Ako
Matsubara, Nobuaki
Sugihara, Masahiro
Ogawa, Hayao
Majima, Shuji
Yu, Channing
Ueno, Suguru
Takano, Toshimi
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS1116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1116
引用
收藏
页数：5
相关论文
共 50 条
[31]   First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+metastatic breast cancer (MBC). [J].
Alsina, Maria ;
Boni, Valentina ;
Schellens, Jan H. M. ;
Moreno, Victor ;
Bol, Kees ;
Westendorp, Martine ;
Sirulnik, L. Andres ;
Tabernero, Josep ;
Calvo, Emiliano .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[32]   Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2-metastatic breast cancer with an ESR1 mutation [J].
Goetz, Matthew ;
Wander, Seth ;
Bachelot, Thomas ;
Batist, Gerald ;
Cortes, Javier ;
Cristofanilli, Massimo ;
Curigliano, Giuseppe ;
de Nonneville, Alexandre ;
Yam, Einav Nili-Gal ;
Jhaveri, Komal ;
Ma, Cynthia ;
Parsons, Heather ;
Rugo, Hope ;
Sammons, Sarah ;
Stover, Daniel ;
Twelves, Chris ;
Bardia, Aditya ;
Plourde, Paul V. ;
Portman, David J. ;
Damodaran, Senthil .
CANCER RESEARCH, 2024, 84 (09)
[33]   Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma [J].
Lesokhin, Alexander ;
Iida, Shinsuke ;
Stevens, Don ;
Gabayan, Afshin Eli ;
Ma, Wei Dong ;
Sullivan, Sharon ;
Raab, Marc-Steffen .
BLOOD, 2021, 138
[34]   A first-in-human phase 1, multicenter, open-label study of M3554, a novel anti-GD2 antibody-drug conjugate (ADC), in patients with advanced solid tumors Free [J].
Italiano, Antoine ;
Yonemori, Kan ;
Haddox, Candace L. ;
Ahnert, Jordi R. ;
Penel, Nicolas ;
Schoffski, Patrick ;
Habermehl, Christina ;
Sanz, Vanesa P. ;
Demetri, George .
CANCER RESEARCH, 2025, 85 (08)
[35]   Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE) [J].
Woodward, Natasha ;
De Boer, Richard H. ;
Redfern, Andrew ;
White, Michelle ;
Young, Jennifer ;
Truman, Matt ;
Beith, Jane .
CLINICAL BREAST CANCER, 2019, 19 (03) :216-224
[36]   A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer [J].
Hurvitz, S. A. ;
Galsky, M. D. ;
Shahidi, J. ;
Zhang, G. ;
Raza, S. ;
Necchi, A. .
ANNALS OF ONCOLOGY, 2018, 29
[37]   Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer [J].
Michael R. Clemens ;
Oleg A. Gladkov ;
Elaina Gartner ;
Vladimir Vladimirov ;
John Crown ;
Joyce Steinberg ;
Fei Jie ;
Anne Keating .
Breast Cancer Research and Treatment, 2015, 149 :171-179
[38]   Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer [J].
Clemens, Michael R. ;
Gladkov, Oleg A. ;
Gartner, Elaina ;
Vladimirov, Vladimir ;
Crown, John ;
Steinberg, Joyce ;
Jie, Fei ;
Keating, Anne .
BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) :171-179
[39]   A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study [J].
Song, Na ;
Teng, Yuee ;
Shi, Jing ;
Teng, Zan ;
Jin, Bo ;
Qu, Jinglei ;
Zhang, Lingyun ;
Yu, Ping ;
Zhao, Lei ;
Wang, Jin ;
Li, Aodi ;
Tong, Linlin ;
Jiang, Shujie ;
Liu, Yang ;
Yin, Liusong ;
Jiang, Xiaoling ;
Xu, Tie ;
Cui, Jian ;
Qu, Xiujuan ;
Liu, Yunpeng .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[40]   An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+or HER2-low unresectable or metastatic (M) breast cancer (BC) [J].
George, M. ;
Frenel, J-S. ;
Cortes, J. ;
Schmidt, M. ;
Garcia Saenz, J. A. ;
Blau, S. ;
Abdulla, N. E. ;
Nishimura, M. ;
Sakai, H. ;
Babu, S. ;
McAndrew, N. P. ;
Ali, A. ;
Pavic, M. ;
Jhaveri, K. ;
Jones, J. M. ;
Rugo, H. S. ;
Mody, K. ;
Smith, A. D. ;
Yamashita, T. .
ANNALS OF ONCOLOGY, 2024, 35 :S404-S404
12345